Nov 20, 2009 (SmarTrend(R) News Watch via COMTEX) ----11/20/2009 - Pfizer (NYSE:PFE) announced that the FDA approved its Revatio Injection. Revatio is the only FDA-approved phosphodiesterase-5 (PDE5) inhibitor available in both tablet and intravenous formulations, according to the company. It is used for the treatment of adults that have pulmonary arterial hypertension in order to improve exercise ability and delay clinical worsening. Vice president of pulmonary vascular disease, clinical development and medical affairs for Pfizer, Dr. Cara Cassino, said, "The approval of Revatio Injection is a clear demonstration of Pfizer's commitment to developing treatments addressing the unmet needs of patients with pulmonary arterial hypertension. This important milestone highlights the Specialty Care business unit's dedication to advancing treatments for serious and life-threatening conditions such as pulmonary vascular disease."

Write to Chip Brian at cbrian@tradethetrend.com

---------------------------------------------------------------------------------------------

SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com.

Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.TradeTheTrend.com/signup.html

Copyright, Comtex News Network, Inc. 2009
   
   **********************************************************************
   
   As of Monday, 11-16-2009 23:59, the latest Comtex SmarTrend� Alert, 
   an automated pattern recognition system, indicated an UPTREND on 
   03-13-2009 for PFE @ $14.28.
   
   For more information on SmarTrend, contact your market data
   provider or go to www.mysmartrend.com
   
   SmarTrend is a registered trademark of Comtex News Network, Inc.
   Copyright � 2004-2009 Comtex News Network, Inc. All rights reserved.